Font Size




Menu Style



HemoSpec will combine three highly performing, complementary biophotonic technologies into one device to allow multiplexed data collection and analysis and leading 

to an innovative crosscutting device based on optical technology. Full characterization of patient’s blood will be available from minimal amounts (1-2 ml), including:

  • hemogram count by using digital inline holographic microscopy,
  • determination of four different biomarker concentrations in the plasma by means of parallel multiplexed fluorescence analysis. The biomarker panel of HemoSpec contains established biomarkers, such as procalitonin (PCT), interleukin 6 (IL-6) and C-reactive protein (CRP) as well as the relatively new prognostic biomarker suPAR. 
  • detailed Raman spectroscopic characterization of the leukocytes yielding an information-rich fingerprint of the cells which encodes the overall chemical composition and molecular structure Blood cells of patients from different groups (SIRS, sepsis, severe sepsis/septic shock) show different fingerprint features in their Raman spectra and therefore allow a differentiation between inflammation and infection from the Raman spectra. Furthermore, different pathogen groups will cause different reactions in the immune cells and therefore, lead to different Raman cell spectra.

This complete information on biomarker and immune cell response will comprehensively characterize patients at high risk (e.g. sepsis patients) and their specific immune response on a high level of complexity. The full, individualized information provided by HemoSpec will enable a better subclassification of the patient groups and therefore, improve the diagnostic accuracy of the final device and help the treating clinician.